BioCentury
ARTICLE | Product Development

Trevena goes for MOR than morphine

A mixed panel on oliceridine could leave the door open for collecting more data

October 13, 2018 4:17 AM UTC

FDA’s Anesthetic and Analgesic Drug Products Advisory Committee meeting on pain candidate oliceridine from Trevena Inc. gave the agency little reason to reverse its skepticism about the molecule’s benefits and risks. But it did leave a door ajar for the company to collect more data to improve its case.

On Oct. 11, the panel voted 8-7 against approval...